Get started
Author

Magdalini Migkou

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
2008 · M.A. Dimopoulos, E. Kastritis, et al. · Annals of Oncology · 437
PDF
Emerging treatment strategies for COVID-19 infection
2020 · Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al. · Clinical and Experimental Medicine · 326
PDF
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
2007 · E. Kastritis, A. Anagnostopoulos, et al. · Haematologica · 191
PDF
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
2012 · E Kastritis, E Terpos, et al. · Leukemia · 157
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
2021 · Evangelos Terpos, Maria Gavriatopoulou, et al. · Blood Cancer Journal · 123
PDF
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
2010 · M A Dimopoulos, E Kastritis, et al. · Leukemia · 119
Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors
2009 · Meletios A. Dimopoulos, Maria Roussou, et al. · Clinical Lymphoma & Myeloma · 111
Cardiac and renal complications of carfilzomib in patients with multiple myeloma
2017 · Meletios A. Dimopoulos, Maria Roussou, et al. · Blood Advances · 106
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients
2012 · Lia A. Moulopoulos, Meletios A. Dimopoulos, et al. · American Journal of Hematology · 97
PDF
Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis
2016 · Meletios A. Dimopoulos, Maria Roussou, et al. · American Journal of Hematology · 92
PDF
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
2016 · Efstathios Kastritis, Evangelos Terpos, et al. · Haematologica · 88
Treatment of light chain deposition disease with bortezomib and dexamethasone
2008 · E. Kastritis, M. Migkou, et al. · Haematologica · 77
PDF
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens
2008 · Maria Roussou, Efstathios Kastritis, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 77
Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications
2012 · Ourania Nicolatou-Galitis, Magdalini Migkou, et al. · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · 75
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy
2017 · Efstathios Kastritis, Maria Gavriatopoulou, et al. · American Journal of Hematology · 73
PDF
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents
2010 · Maria Roussou, Efstathios Kastritis, et al. · Leukemia Research · 72
Dickkopf-1: a suitable target for the management of myeloma bone disease
2009 · Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, et al. · Expert Opinion on Therapeutic Targets · 68
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment
2010 · Meletios A. Dimopoulos, Dimitrios Christoulas, et al. · European Journal Of Haematology · 67
Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents
2010 · L A Moulopoulos, M A Dimopoulos, et al. · Leukemia · 65
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents
2017 · Maria Gavriatopoulou, Efstathios Kastritis, et al. · Blood · 59
Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies
2015 · Efstathios Kastritis, Maria Roussou, et al. · American Journal of Hematology · 59
PDF
Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma
2020 · Shaji K. Kumar, Magdalini Migkou, et al. · Blood · 57
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid
2010 · E. Terpos, D. Christoulas, et al. · Annals of Oncology · 56
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
2019 · Efstathios Kastritis, Ioanna Dialoupi, et al. · Blood Advances · 55
Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma
2009 · M Roussou, A Tasidou, et al. · Leukemia · 55
Works count: 378
Citation count: 4,828
H-index: 36
I10-index: 93
Year
Topic
Type